ArticleOphthalmology science2026
Phase I/IIa Study of an Intravitreal Optogenetic Therapy (AGN-151597) in Patients with Advanced Retinitis Pigmentosa.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objective: Retinitis pigmentosa is an incurable, inherited retinal disease that causes vision loss and blindness. We evaluated the safety and preliminary efficacy of AGN-151597, a mutation-independent optogenetic therapy encoding channelrhodopsin-2, in patients with advanced retinitis pigmentosa. Design: First-in-human, phase I/IIa, open-label, dose-escalation study (1 study eye/participant). Participants: Participants had advanced retinitis pigmentosa with severely impaired visual function. Methods: Participants received an intravitreal injection of low-dose (4.3 × 10 Main Outcome Measures: The primary safety endpoint was safety at 6 months as assessed by intraocular pressure and changes in visual acuity, full-field sensitivity, ambulation, and visual anatomical parameters. Efficacy measures included changes in visual acuity, full-field stimulus threshold (FST), ambulation, object detection/discrimination, visual evoked potentials, electroretinography, and visual function-related quality of life (questionnaire). Results: Fourteen patients (median age 62 years) were enrolled. AGN-151597 treatment resulted in no clinically significant changes in ocular safety assessments. Most treatment-emergent adverse events (TEAEs) were ocular; none were severe. The most common treatment-related TEAE was transient increased intraocular pressure (n = 3). No clinically significant efficacy was observed. Full-field stimulus threshold measurements in both eyes showed good agreement between the screening and baseline visits, with coefficients of repeatability of 6.2 for blue light, 2.7 for red light, and 5.3 for white light. Overall mean FST in study eyes at baseline was -13.5 dB for blue light, -1.0 dB for red light, and -5.2 dB for white light. Participants' mean FST changed similarly in both eyes over 24 months for each light stimulus. Conclusions: There was no evidence of AGN-151597 efficacy in slowing vision decline in patients with advanced retinitis pigmentosa. However, the absence of safety concerns over 5 years after intravitreal administration of an adeno-associated virus type 2 vector-delivered genetic medicine is encouraging and supports further gene therapy endeavors to enhance visual function in this devastating retinal disease. Full-field stimulus threshold is a reliable test in patients with poor vision. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.